The world has more promising discovered drug candidates than ever. The problem is developing them. We built Formation Bio to fix that, using AI to develop drugs faster and with a higher likelihood of success. Thank you @amyfeldman and @Forbes telling the story of our mission, and our vision for the future of pharma. forbes.com/sites/amyfeldman/…

Phyla aggregates 90 tools across 27 biomedical sources and ties every single claim to a checkable citation. Benchmarked against two other frontier AI life-science platforms, writing full research dossiers across 7 target–disease pairs: 99.7% of Phyla’s statements carried a citation (vs. 87% and 86%), and 92% of its claims were fully backed by the cited source (vs. 80% and 67%). See how we built it, and how it’s being used at Formation: formation.bio/blog/phyla

Formation Bio made #7 on @FastCompany's Best Workplaces for Innovators 2026. This piece highlights one of our internal systems: ARK (AI-ready Repository of Knowledge), our in-house AI platform that connects all internal systems and data across the company. Full write-up here: fastcompany.com/91591991/for… Our open roles: formation.bio/careers Learn more about ARK: formation.bio/blog/ark-mcp-g…

Proud to be selected as #7 on @FastCompany's 2026 100 Best Workplaces for Innovators, plus as a winner on the Biotech, Healthcare & Life Sciences list. Find us on the full list: fastcompany.com/best-workpla… We're hiring across New York and Boston now: formation.bio/careers

"In a world of drug discovery abundance, the scarce capability is no longer making drugs, but rather, knowing which drugs are worth developing." @BenjamineYLiu, co-founder and CEO of Formation Bio, explains how AI will transform the economics of the pharma industry - link in replies

What drew Mike Ehlers, our new Chief Scientific Officer and Head of R&D, to Formation Bio? Hear it in his own words. More on Mike’s life outside the lab in today’s @statnews executive moves column: statnews.com/pharmalot/2026/…

In his latest blog, our Principal Engineer Kenny Peng revisits the Unix philosophy (do one thing well, compose freely, shared interfaces) as a blueprint for agentic system design. Using biopharma as the test case, he breaks down why hardcoded pipelines break down over time, and what composable alternatives require. Read here: linkedin.com/posts/kpeng_the…

.@BenjamineYLiu has raised more than $600M for his AI-native biopharma company - and he's hiring! @formationbio is applying AI to drug development, with a mission to bring new treatments to patients faster and more efficiently. The team is hiring across the board, including: - Director, Brand & Communications - Senior Director or VP, Product - General Manager (Drug Asset Lead) - Principal Data Scientist, Medical Imaging - Data Scientist, Portfolio Optimization - Director, Business Development - Search & Evaluation Full story + list of open roles in thread!

Formation Bio said it has appointed former Biogen research head Michael Ehlers as its chief scientific officer, bringing a seasoned drug and biotech veteran into the AI-focused health startup. bloomberg.com/news/articles/…

Excited to share that Mike Ehlers is joining @formationbio as Chief Scientific Officer and Head of R&D. Over the course of his career as a scientist, drug developer, and investor, Mike has advanced 40+ drugs into the clinic, with approvals spanning Alzheimer's, ALS, MS, hemophilia, and SMA. Welcome to the team, Mike!

The @decodingbio AI x Bio Summit lands in NYC this week, and our CEO and Co-Founder @BenjamineYLiu will be speaking at the @awscloud Executive Reception that follows, joining a panel on what it takes to scale AI in pharma. Read more and request to join: luma.com/iylrgtia

This Thursday, our Co-Founder & CEO @BenYLiu takes the stage at @decodingbio's AI x Bio Summit at the @NYSE to discuss how platform companies are creating new business models in biotech – alongside voices from @Nabla Bio, @Manifold Bio, and @Dimension Capital. Link to register: events.decodingbio.com/summi…